Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
about
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsSimeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparisonRole of liver transplantation in human immunodeficiency virus positive patientsHepatitis C: Treatment of difficult to treat patientsHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?New treatments for genotype 1 chronic hepatitis C - focus on simeprevirImmuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexusPotential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected PatientsTreatment optimization for HIV/HCV co-infected patients.Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection TreatmentAccess and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Hepatitis C in Argentina: epidemiology and treatment.The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patientsAntiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patientsHepatitis C virus infection in the human immunodeficiency virus infected patient.Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionDirect-acting antivirals for chronic hepatitis C.Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.Care at the Crossroads: Navigating the HIV, HCV, and Substance Abuse Syndemic.CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adultsClinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinManaging HIV/hepatitis C co-infection in the era of direct acting antivirals.HCV and HIV co-infection: mechanisms and management.Update on Hepatitis C Virus and HIV Coinfection.Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary CarePeginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.Recent advances in management of the HIV/HCV coinfected patient.Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea.HCV cure for everyone or which challenges remain?CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentSofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection.
P2860
Q26747561-7E46CE1C-ABEE-43E8-A720-A142A5C58ACDQ26769709-4A0415D0-BEE9-480D-A71C-97DB502E0AA4Q26775931-BA204E00-E211-453B-9457-1CAD23103055Q26798465-A9BF781F-2408-4E46-9CC1-993CC62071FCQ26798469-ED62F8C2-4DD2-4FC6-8F2B-26A1C8DACE21Q26853138-F90536D3-5A7F-49A2-BCBD-7E394B44748DQ26991958-F5859497-B20A-42FF-B827-6DC00E48E35DQ28550423-94F20536-D582-461C-B37B-21C78A61B0DEQ30235034-6478354D-6FA3-4AB7-927C-4FE4FAF8D6E5Q31076943-5796C5CD-6C8B-4E87-B034-6D122E88C236Q33422417-416113BC-663E-46F2-91F5-D3994FCECC8DQ33423922-021DED51-1740-4077-8F7C-63A227AC39F5Q33576161-C8AB3B06-2AC0-4B89-81D5-08123FBBB3E6Q33699364-D39B67CA-8D47-48A1-827C-C23631C8C278Q33706886-2E6BABDE-4391-425D-B14A-2EEF73636B57Q33710740-4B26FAB1-974E-4F85-8CE3-B59EF9536FDBQ33889885-BF802813-45FF-49FE-AB86-0A6DA2B310A6Q33946635-E66BA51F-870C-4529-8A8A-1E0B1718C06FQ34168504-C494316F-429E-4C3D-9900-F2D19B039E7DQ34298877-1D906365-96C5-45F8-AD3C-0B49B8C06735Q34557595-4554F5F5-24AC-424C-B916-7ADD6B46EE09Q34626591-6F928E9B-FFCD-4A60-840B-41FA5228172FQ34702334-B54D473D-0882-466B-8669-44A5993AB896Q34775524-4B590A4C-F9B8-4D8B-A067-411F260FFE76Q34802167-8BFA2CD4-EC50-4250-AEC1-3719B78A8597Q35042619-D8EBA715-D1C3-4DD9-B3B4-8DA0E07C81B5Q35090634-EC0504BA-2367-4999-8E4C-389DFAFF292FQ35906047-532D10BB-A1E2-4A43-B820-5E4EE4E4039CQ35999442-B56F46A0-43B7-4C9B-9BBB-537AC70415DFQ36015496-EB84FC66-F47A-4D1D-940F-0576D3230748Q36330435-0D91D3AD-F74D-4380-B204-FE8F17CE7801Q36575497-C34272AB-44BA-4D62-9476-7EB264E3F241Q36948099-09AE7CEC-36B0-4130-8C6C-A2A4DB8247E6Q36967076-E6760F6E-40BE-425E-AB85-3975E440BA21Q37081478-57B71390-3113-412B-AFCE-2E0AB01E305BQ37098242-2B40E836-04D9-4D8B-A576-C8C26CA745ADQ37100669-D224EFF5-5152-4449-9B8F-138B79E28026Q37202576-270D3144-F103-4B3F-B1AC-E5C6B643AF94Q37455611-FB2C6496-9FDE-480B-A676-5608A9482813Q37628545-D6C0196A-3ED9-47F1-BA48-2A59FC2EF304
P2860
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Boceprevir versus placebo with ...... ind, controlled phase 2 trial.
@en
Boceprevir versus placebo with ...... ind, controlled phase 2 trial.
@nl
type
label
Boceprevir versus placebo with ...... ind, controlled phase 2 trial.
@en
Boceprevir versus placebo with ...... ind, controlled phase 2 trial.
@nl
prefLabel
Boceprevir versus placebo with ...... ind, controlled phase 2 trial.
@en
Boceprevir versus placebo with ...... ind, controlled phase 2 trial.
@nl
P2093
P1476
Boceprevir versus placebo with ...... lind, controlled phase 2 trial
@en
P2093
Anita Y M Howe
Carmen Mak
Curtis Cooper
Hugo Fainboim
Janice Wahl
Jihad Slim
Josep Mallolas
Larissa Wenning
Mark Sulkowski
P05411 study investigators
P304
P356
10.1016/S1473-3099(13)70149-X
P577
2013-06-12T00:00:00Z